Cargando…

Efficacy and Safety of Dulaglutide Versus Sitagliptin After 52 Weeks in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-5). Diabetes Care 2014;37:2149–2158

Detalles Bibliográficos
Autores principales:	Nauck, Michael, Weinstock, Ruth S., Umpierrez, Guillermo E., Guerci, Bruno, Skrivanek, Zachary, Milicevic, Zvonko
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Diabetes Association 2015
Materias:	Erratum
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5321253/ https://www.ncbi.nlm.nih.gov/pubmed/25715416 http://dx.doi.org/10.2337/dc15-er03

Ejemplares similares

Efficacy and Safety of Dulaglutide Versus Sitagliptin After 52 Weeks in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-5)
por: Nauck, Michael, et al.
Publicado: (2014)

Safety and efficacy of once‐weekly dulaglutide versus sitagliptin after 2 years in metformin‐treated patients with type 2 diabetes (AWARD‐5): a randomized, phase III study
por: Weinstock, R. S., et al.
Publicado: (2015)

Efficacy and Safety of Dulaglutide 3.0 mg and 4.5 mg Versus Dulaglutide 1.5 mg in Metformin-Treated Patients With Type 2 Diabetes in a Randomized Controlled Trial (AWARD-11)
por: Frias, Juan P., et al.
Publicado: (2021)

Effect of once‐weekly dulaglutide versus insulin glargine in people with type 2 diabetes and different baseline glycaemic patterns: A post hoc analysis of the AWARD‐2 clinical trial
por: Giorgino, Francesco, et al.
Publicado: (2019)

Comment on Brethauer et al. Bariatric Surgery Improves the Metabolic Profile of Morbidly Obese Patients With Type 1 Diabetes. Diabetes Care 2014;37:e51–e52
por: Middelbeek, Roeland J.W., et al.
Publicado: (2014)

Response to Comments on Brethauer et al. Bariatric Surgery Improves the Metabolic Profile of Morbidly Obese Patients With Type 1 Diabetes. Diabetes Care 2014;37:e51–e52
por: Kirwan, John P., et al.
Publicado: (2014)

Achieving the composite endpoint of glycated haemoglobin <7.0%, no weight gain and no hypoglycaemia in the once‐weekly dulaglutide AWARD programme
por: Dungan, K. M., et al.
Publicado: (2016)

Response to Comment on Cefalu et al. The Alarming and Rising Costs of Diabetes and Prediabetes: A Call for Action! Diabetes Care 2014;37:3137–3138
por: Cefalu, William T., et al.
Publicado: (2015)

Response to Comment on Home et al. Insulin Therapy in People With Type 2 Diabetes: Opportunities and Challenges? Diabetes Care 2014;37:1499–1508
por: Home, Philip, et al.
Publicado: (2014)

OR26-08 Efficacy and Safety of Higher Dulaglutide Doses (3.0 MG and 4.5 MG) When Added to Metformin in Patients With Type 2 Diabetes: A Phase 3, Randomized, Double-Blind, Parallel ARM Study (Award-11)
por: Frias, Juan Pablo, et al.
Publicado: (2020)

Comment on Vimalananda et al. Depressive Symptoms, Antidepressant Use, and the Incidence of Diabetes in the Black Women’s Health Study. Diabetes Care 2014;37:2211–2217
por: Kivimäki, Mika, et al.
Publicado: (2015)

Response to Comment on Hedderson et al. Prepregnancy SHBG Concentrations and Risk for Subsequently Developing Gestational Diabetes Mellitus. Diabetes Care 2014;37:1296–1303
por: Hedderson, Monique M., et al.
Publicado: (2014)

Response to Comment on Doyle et al. Closed-Loop Artificial Pancreas Systems: Engineering the Algorithms. Diabetes Care 2014;37:1191–1197
por: Doyle, Francis J., et al.
Publicado: (2014)

Erratum. Dietary Protein Intake and Incidence of Type 2 Diabetes in Europe: The EPIC-InterAct Case-Cohort Study. Diabetes Care 2014;37:1854–1862
por: van Nielen, Monique, et al.
Publicado: (2015)

Response to Comment on Sarkar et al. Exenatide Treatment for 6 Months Improves Insulin Sensitivity in Adults With Type 1 Diabetes. Diabetes Care 2014;37:666–670
por: Sarkar, Gayatri, et al.
Publicado: (2014)

Gut Microbiota Metabolites of Dietary Lignans and Risk of Type 2 Diabetes: A Prospective Investigation in Two Cohorts of U.S. Women. Diabetes Care 2014;37:1287–1295
por: Sun, Qi, et al.
Publicado: (2014)

Erratum. Increased Risk of Fracture and Postfracture Adverse Events in Patients With Diabetes: Two Nationwide Population-Based Retrospective Cohort Studies. Diabetes Care 2014;37:2246–2252
por: Liao, Chien-Chang, et al.
Publicado: (2017)

Response to Comment on O’Connor et al. Randomized Trial of Telephone Outreach to Improve Medication Adherence and Metabolic Control in Adults With Diabetes. Diabetes Care 2014;37:3317–3324
por: O’Connor, Patrick J., et al.
Publicado: (2015)

Erratum. A Randomized Controlled Trial of Cognitive Behavioral Therapy for Adherence and Depression (CBT-AD) in Patients With Uncontrolled Type 2 Diabetes. Diabetes Care 2014;37:625–633
por: Safren, Steven A., et al.
Publicado: (2016)

Study of Hamamatsu R2149 phototetrodes in magnetic field
por: Bonesini, M, et al.
Publicado: (1996)

Effect of once weekly dulaglutide by baseline beta‐cell function in people with type 2 diabetes in the AWARD programme
por: Mathieu, Chantal, et al.
Publicado: (2018)

Response to Comment on Grimaldi et al. Association of Obstructive Sleep Apnea in Rapid Eye Movement Sleep With Reduced Glycemic Control in Type 2 Diabetes: Therapeutic Implications. Diabetes Care 2014;37:355–363
por: Mokhlesi, Babak, et al.
Publicado: (2014)

Report from LHC MD 2158: IR-nonlinear studies
por: Maclean, Ewen Hamish, et al.
Publicado: (2018)

Effect of dulaglutide 3.0 and 4.5 mg on weight in patients with type 2 diabetes: Exploratory analyses of AWARD‐11
por: Bonora, Enzo, et al.
Publicado: (2021)

Dulaglutide and Insulin: How Can the AWARD Studies Help Guide Clinical Practice?
por: MacIsaac, Richard J.
Publicado: (2020)

Relationship between weight change and glycaemic control in patients with type 2 diabetes receiving once‐weekly dulaglutide treatment
por: Umpierrez, G. E., et al.
Publicado: (2016)

Sitagliptin, sitagliptin and metformin, or sitagliptin and amitriptyline attenuate streptozotocin-nicotinamide induced diabetic neuropathy in rats
por: Sharma, Ashish Kumar, et al.
Publicado: (2012)

Advances in the treatment of type 2 diabetes: impact of dulaglutide
por: Thompson, Angela M, et al.
Publicado: (2016)

A 24‐week study to evaluate the efficacy and safety of once‐weekly dulaglutide added on to glimepiride in type 2 diabetes (AWARD‐8)
por: Dungan, K. M., et al.
Publicado: (2016)

Response to Comment on Palmas et al. Results of the Northern Manhattan Diabetes Community Outreach Project: A Randomized Trial Studying a Community Health Worker Intervention to Improve Diabetes Care in Hispanic Adults. Diabetes Care 2014;37:963–969
por: Palmas, Walter, et al.
Publicado: (2015)

Euglycemic diabetic ketoacidosis after the initiation of dulaglutide in patient with type 2 diabetes
por: Alduraibi, Rabia Khalid, et al.
Publicado: (2023)

Efficacy and Safety of Once-Weekly Dulaglutide in Elderly Chinese Patients with Type 2 Diabetes: A Post Hoc Analysis of AWARD-CHN Studies
por: Kuang, Jian, et al.
Publicado: (2020)

Addition of sitagliptin to ongoing metformin monotherapy improves glycemic control in Japanese patients with type 2 diabetes over 52 weeks
por: Kadowaki, Takashi, et al.
Publicado: (2012)

Sitagliptin added to treatment with ongoing pioglitazone for up to 52 weeks improves glycemic control in Japanese patients with type 2 diabetes
por: Kashiwagi, Atsunori, et al.
Publicado: (2011)

A 52‐week randomized controlled trial of ipragliflozin or sitagliptin in type 2 diabetes combined with metformin: The N‐ISM study
por: Kitazawa, Masaru, et al.
Publicado: (2021)

PB2158: EXPLORING THE BIOLOGICAL ROLE OF LILRA4 IN MANTLE CELL LYMPHOMA
por: Blum, M. K., et al.
Publicado: (2022)

2158. An outbreak of carbapenem-resistant Acinetobacter baumannii at a tertiary hospital in Ethiopia
por: Adbaru, Mulatu G, et al.
Publicado: (2023)

The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Type 2 Diabetes Patients (TROPHIES): Design and Baseline Characteristics
por: García-Pérez, Luis-Emilio, et al.
Publicado: (2021)

Effect of sitagliptin on proteinuria in patients with type 2 diabetes – A renoprotective effect of sitagliptin
por: Narimani, Rouhollah, et al.
Publicado: (2021)

Efficacy and Safety of Switching From the DPP-4 Inhibitor Sitagliptin to the Human GLP-1 Analog Liraglutide After 52 Weeks in Metformin-Treated Patients With Type 2 Diabetes: A randomized, open-label trial
por: Pratley, Richard E., et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_0jhvctppchiquuu3he7tekr067